Purpose: This study investigated the efficacy and safety of monthly risedronate, with and without cholecalciferol, on 25-hydroxyvitamin D (25[OH]D) levels and bone markers in Korean patients with osteoporosis.
Methods: A randomized, double-blinded, prospective, 16-week clinical trial was conducted in ten hospitals. A total of 150 subjects with osteoporosis were randomized to one of the two treatment groups: RSDM+ (monthly risedronate 150 mg and cholecalciferol 30,000 IU combined in a single pill, n = 74) or RSDM (monthly risedronate 150 mg alone, n = 76). We measured serum levels of 25-hydroxyvitamin D (25[OH]D), parathyroid hormone (PTH), and bone markers, as well as performing muscle-function tests at baseline and after 16 weeks of treatment.
Results: After 16 weeks, serum 25(OH)D levels significantly increased from 17.8 to 26.8 ng/mL in the RSDM+ group, but did not change in the RSDM group. The RSDM+ group exhibited significantly decreased serum PTH from 46 to 36.7 pg/mL, while the RSDM group showed a tendency for PTH to increase from 38 to 40.6 pg/mL. In both groups, serum bone-specific alkaline phosphatase and C-terminal telopeptide rapidly declined, with significance at 16 weeks; there were no significant differences between the groups.
Conclusion: A once-monthly pill of risedronate and cholecalciferol provided equivalent antiresorptive efficacy to risedronate alone in terms of bone turnover and improved 25(OH)D levels over the 16-week treatment period without significant adverse events in Korean patients with osteoporosis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3673862 | PMC |
| http://dx.doi.org/10.2147/CIA.S44395 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Potential Role for Nivolumab in the Treatment of Fibrous Dysplasia-Related Pain.
JCEM Case Rep
October 2024
Division of Endocrinology, Department of Medicine, Western University, London, ON N6A 5C1, Canada.
Article Synopsis
- * A 50-year-old woman with FD experienced significant headaches and was treated with monthly IV pamidronate, which helped alleviate her pain but was hard to reduce due to recurring symptoms; other oral medications were ineffective.
- * After being diagnosed with metastatic melanoma and starting nivolumab treatment, her long-term headaches completely resolved, suggesting that nivolumab may have a role in managing pain associated with fibrous dysplasia by inhibiting osteoclast activity.
Twelve-month resistance and impact exercise program or risedronate provides a relative benefit to hip bone structure in postmenopausal women: results from a randomized controlled trial.
Osteoporos Int
May 2024
College of Allied Health Professions, University of Nebraska Medical Center, Omaha, NE, USA.
Unlabelled: Bone strength estimates are important for fracture prevention. This study compared bone strength changes in postmenopausal women with low bone mass who were assigned to 12 months of exercise, a bone medication, or control. Exercise and bone medications benefited structure at the hip.
View Article and Find Full Text PDFThe effectiveness of ibandronate in reducing the risk of nonvertebral fractures in women with osteoporosis: systematic review and meta-analysis of observational studies.
Int J Clin Pharm
April 2024
Laboratory of Social Pharmacy and Public Health, Faculty of Pharmacy, Polo Ciencias da Saude, University of Coimbra, Azinhaga de Santa Comba, Celas, 3000-548, Coimbra, Portugal.
Background: Ibandronate is effective in reducing the risk of vertebral fractures, but experimental evidence offers conflicting results regarding nonvertebral fractures. Real-world evidence has been published evaluating the anti-nonvertebral fracture effect of ibandronate.
Aim: This meta-analysis of observational studies assessed the effectiveness of ibandronate in reducing the risk of nonvertebral fractures in women with osteoporosis.
Strategies to reduce the onset of sleeve gastrectomy associated bone loss (STRONG BONES): Trial design and methods.
Contemp Clin Trials Commun
August 2023
Department of Health and Exercise Science, Wake Forest University, Winston-Salem, NC, USA.
Background: Despite recognized improvements in obesity-related comorbidities, mounting evidence implicates surgical weight loss in the onset of skeletal fragility. Sleeve gastrectomy (SG) is the most commonly performed bariatric procedure and is associated with 3-7% axial bone loss in the year following surgery. Bisphosphonates are FDA-approved medications for the prevention and treatment of age-related bone loss and may represent a strategy to reduce bone loss following SG surgery.
View Article and Find Full Text PDFThe clinical utility of TRACP-5b to monitor anti-resorptive treatments of osteoporosis.
Osteoporos Int
June 2022
Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK.
Unlabelled: TRACP-5b can be used to monitor the response of treatments in osteoporosis. We investigated the effect of feeding on levels of TRACP-5b and how these markers perform in a clinical setting. After feeding, there was no effect on levels TRACP-5b.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!